In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...
Dallas, TX - The addition of natriuretic peptide testing to the traditional clinical evaluation of patients with dyspnea of suspected cardiac origin cut the duration of emergency-department visits by ...
June 18, 2009 (St Paul, Minnesota) — Plasma levels of N-terminal fragment of B-type natriuretic peptide (NT-proBNP) were significantly increased in association with asymptomatic LV systolic or ...
NT-proBNP testing should become compulsory for referring patients to specialist heart failure services to improve diagnosis of the condition in primary care, an expert report has said. The Alliance ...
"HF algorithms are starting to recognize and include NT-proBNP in identifying stage B HF…Studies such as ours could provide insight and guidance as to when repeat measures may be useful. Future work ...
Pharmacokinetics (PK) and pharmacodynamics (PD) in First-MIND: A phase Ib, open-label, randomized study of tafasitamab (tafa) ± lenalidomide (LEN) in addition to R-CHOP in patients (pts) with newly ...
NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most significant is ...
Phase I study of sunitinib (S) in combination with metronomic dosing of cyclophosphamide and methotrexate (CM) in patients with metastatic breast cancer (MBC) No significant financial relationships to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results